1384475-22-2

Upstream product

• 1354808-43-7 3-(4-bromophenyl)-3-o-tolylpropanoic acid 
• 1354808-44-8 3-(4-bromo-phenyl)-N-methoxy-N-methyl-3-o-tolyl-propionamide 
• 1354810-21-1 (R)-3-(4-bromo-phenyl)-N-methoxy-N-methyl-3-o-tolyl-propionamide 
• 1354812-21-7 (R)-3-(4-bromophenyl)-1-(6-methoxypyridin-3-yl)-3-o-tolylpropan-1-one 
• 1354812-22-8 (R)-5-(3-(4-bromophenyl)-3-o-tolylpropanoyl)pyridin-2(1H)-one 
• 1126-09-6 4-carbethoxypiperidine 
• 1354812-23-9 (R)-5-(3-(4-bromophenyl)-3-o-tolylpropanoyl)-1-methylpyridin-2(1H)-one 
• 1122-91-4 4-bromo-benzaldehyde 
• 42205-33-4 (E)-ethyl 3-(4-bromophenyl)-2-cyanoacrylate 
• 1354808-42-6 ethyl 3-(4-bromophenyl)-2-cyano-3-o-tolylpropanoate 
• 33872-80-9 o-tolyl magnesium chloride 

Relevant academic research and scientific papers

1-CYCLOALKYL- OR 1-HETEROCYCLYL-HYDROXYIMINO-3-PHENYL-PROPANES

This invention relates to novel 1-cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes of the formula wherein R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may therefore be useful as medicaments for the treatment of diseases such as type II diabetes.

1-CYCLOALKYL- OR 1-HETEROCYCLYL-HYDROXYIMINO-3-PHENYL-PROPANES

This invention relates to novel 1-cycloalkyl- or l-heterocyclyl-hydroxyimino-3-phen propanes of the formula wherein R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may therefore be useful as medicaments for the treatment of diseases such as type II diabetes.